The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 352:2757-2759 June 30, 2005 Number 26
NextNext

Hypothyroidism Due to Ethionamide

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: Ethionamide (Trecator-SC, Wyeth-Ayerst) is an antimycobacterial drug used as a second-line agent in the treatment of multidrug-resistant tuberculosis. It is structurally similar to methimazole, has been shown to inhibit thyroid hormone synthesis, and was last reported to cause hypothyroidism in 1984.1 Before that report, only three other cases of hypothyroidism related to ethionamide were documented.1 We now report the case of a 57-year-old Indian-American woman with Takayasu's arteritis, coronary artery disease, and multidrug-resistant tuberculosis in whom hypothyroidism developed while she was receiving 250 mg of ethionamide twice daily for three months. She had previously been euthyroid (thyrotropin . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.